Carol Dian Martin

US Patent:

20110152830, Jun 23, 2011

Filed:

Dec 16, 2010

Appl. No.:

12/970777

Inventors:

TIMOTHY L. RUCHTI - Gurnee IL, US
STEVEN R. WEHBA - Carlsbad CA, US
JOHN Harrison THORNLEY - Charlotte NC, US
HARSH DHARWAD - San Diego CA, US
JOANNE Marie WATT - Tower Lakes IL, US
CAROL Dian MARTIN - Charlotte NC, US
SUZANNE WILLEY - San Diego CA, US

Assignee:

HOSPIRA, INC. - Lake Forest IL

International Classification:

A61M 5/14

US Classification:

604504, 604500, 604 9301

Abstract:

In example methods and systems described, a medical device can store information locally and in a separate database on a server, for example. If the device fails, or a patient is moved to a second device, information may be transferred to the second device such that the second device can resume a complex therapy at a point where the initial medical device left off. The data necessary to restart the complex therapy system may include certain underlying patient-specific parameters according to a model capturing the patient's physiological response to the medication in question. As a result, it is not necessary for the second device to restart the complex therapy or regress to an initial set of baseline assumptions.

US Patent:

20130165901, Jun 27, 2013

Filed:

Dec 21, 2012

Appl. No.:

13/725115

Inventors:

William Patrick Burgess - Charlotte NC, US
John Dumas, III - Libertyville IL, US
Ronald Lisiecki - Libertyville IL, US
Carol Dian Martin - Charlotte NC, US
Laura Santana - Charlotte NC, US
John Harrison Thornley - Charlotte NC, US
Joanne Marie Watt - Tower Lakes IL, US

Assignee:

EndoTool, LLC - Charlotte NC

International Classification:

A61M 5/172

US Classification:

604504

Abstract:

In example methods and systems described, insulin therapy for a patient can be determined. At least one of a short-acting subcutaneous insulin dosage recommendation, a correction subcutaneous insulin dosage recommendation, an intravenous insulin dosage recommendation, a recommended amount of carbohydrates to be administered to the patient, or combinations thereof, can be determined. In addition, information indicating a confirmation of a nutrition intake for the patient, and a long-acting insulin-on-board for the patient can be received, and based on this information, a required long-acting subcutaneous or intravenous insulin dosage for the patient can be determined. The short-acting subcutaneous or intravenous insulin dosage recommendation can be adjusted based, at least in part, on a difference between the long-acting insulin-on-board and the required long-acting subcutaneous or intravenous insulin dosage.

US Patent:

20210085870, Mar 25, 2021

Filed:

Nov 20, 2020

Appl. No.:

17/100710

Inventors:

- Charlotte NC, US
WILLIAM PATRICK BURGESS - CHARLOTTE NC, US
JOHN DUMAS, III - LIBERTYVILLE IL, US
RONALD LISIECKI - LIBERTYVILLE NC, US
CAROL DIAN MARTIN - CHARLOTTE NC, US
LAURA SANTANA - CHARLOTTE NC, US
JOHN HARRISON THORNLEY - CHARLOTTE NC, US
JOANNE MARIE WATT - TOWER LAKES IL, US

Assignee:

MONARCH MEDICAL TECHNOLOGIES, LLC - CHARLOTTE NC

International Classification:

A61M 5/172
G16H 50/20
A61B 5/00
A61B 5/145
G16H 20/17
G16H 10/40
G06Q 50/22

Abstract:

In example methods and systems described, insulin therapy for a patient can be determined. At least one of a short-acting subcutaneous insulin dosage recommendation, a correction subcutaneous insulin dosage recommendation, an intravenous insulin dosage recommendation, a recommended amount of carbohydrates to be administered to the patient, or combinations thereof, can be determined. In addition, information indicating a confirmation of a nutrition intake for the patient, and a long-acting insulin-on-board for the patient can be received, and based on this information, a required long-acting subcutaneous or intravenous insulin dosage for the patient can be determined. The short-acting subcutaneous or intravenous insulin dosage recommendation can be adjusted based, at least in part, on a difference between the long-acting insulin-on-board and the required long-acting subcutaneous or intravenous insulin dosage.

US Patent:

20180333535, Nov 22, 2018

Filed:

Jul 30, 2018

Appl. No.:

16/049676

Inventors:

- Charlotte NC, US
William Patrick Burgess - Charlotte NC, US
John Dumas, III - Libertyville IL, US
Ronald Lisiecki - Libertyville NC, US
Carol Dian Martin - Charlotte NC, US
Laura Santana - Charlotte NC, US
John Harrison Thornley - Charlotte NC, US
Joanne Marie Watt - Tower Lakes IL, US

Assignee:

Monarch Medical Technologies, LLC - Charlotte NC

International Classification:

A61M 5/172
G06Q 50/22
G06F 19/00
A61B 5/00
G16H 20/17
G16H 50/20
G16H 10/40
A61B 5/145

Abstract:

In example methods and systems described, insulin therapy for a patient can be determined. At least one of a short-acting subcutaneous insulin dosage recommendation, a correction subcutaneous insulin dosage recommendation, an intravenous insulin dosage recommendation, a recommended amount of carbohydrates to be administered to the patient, or combinations thereof, can be determined. In addition, information indicating a confirmation of a nutrition intake for the patient, and a long-acting insulin-on-board for the patient can be received, and based on this information, a required long-acting subcutaneous or intravenous insulin dosage for the patient can be determined. The short-acting subcutaneous or intravenous insulin dosage recommendation can be adjusted based, at least in part, on a difference between the long-acting insulin-on-board and the required long-acting subcutaneous or intravenous insulin dosage.